Implementation and Uptake of Raltegravir Granules in Newborns Diagnosed With HIV Through Birth Testing in Maternity Settings in Zimbabwe During the COVID-19 Pandemic

Implementation and Uptake of Raltegravir Granules in Newborns Diagnosed With HIV Through Birth Testing in Maternity Settings in Zimbabwe During the COVID-19 Pandemic

Zimbabwe introduced raltegravir (RAL) granules at 14 facilities providing point-of-care HIV birth testing, aiming to initiate all newborns with HIV on a RAL-based regimen. From June 2020 to July 2021, we tested 3172 of the 6989 (45%) newborns exposed to HIV; we diagnosed 59(2%) with HIV infection, o...

Full description

Saved in:
Bibliographic Details
Published in:The Pediatric infectious disease journal
Main Authors: Denoeud-Ndam, Lise, Stecker, Carl, Andifasi, Precious, Mushavi, Angela, Maphosa, Talent, Zondo, Mongiwa, Murandu, Mildrate, Gombakomba, Gladys, Katirayi, Leila, Mungati, More, Bailey, Rebecca, Weber, Rachel, Rivadeneira, Emilia, Hrapcak, Susan
Format: Journal Article
Language:English
Published: Lippincott Williams & Wilkins 20-03-2023
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Zimbabwe introduced raltegravir (RAL) granules at 14 facilities providing point-of-care HIV birth testing, aiming to initiate all newborns with HIV on a RAL-based regimen. From June 2020 to July 2021, we tested 3172 of the 6989 (45%) newborns exposed to HIV; we diagnosed 59(2%) with HIV infection, of whom 27 (46%) initiated RAL. The SARS-CoV-2 coronavirus disease pandemic exacerbated supply chain and trained provider shortages, contributing to low birth testing, RAL uptake and 6-month viral load testing.
ISSN:0891-3668
DOI:10.1097/INF.0000000000003906